Immuron Limited (IMRN)
NASDAQ: IMRN · Real-Time Price · USD
1.920
+0.120 (6.67%)
At close: Sep 10, 2025, 4:00 PM
1.830
-0.090 (-4.69%)
After-hours: Sep 10, 2025, 5:38 PM EDT
Immuron Revenue
In the fiscal year ending June 30, 2025, Immuron had annual revenue of 7.29M AUD with 48.63% growth. Immuron had revenue of 3.29M in the half year ending June 30, 2025, with 169.66% growth.
Revenue (ttm)
7.29M AUD
Revenue Growth
+48.63%
P/S Ratio
2.57
Revenue / Employee
1,041,000 AUD
Employees
7
Market Cap
12.26M USD
Revenue Chart
* This company reports financials in AUD.
Revenue History
Fiscal Year End | Revenue | Change | Growth |
---|---|---|---|
Jun 30, 2025 | 7.29M | 2.38M | 48.63% |
Jun 30, 2024 | 4.90M | 3.10M | 171.67% |
Jun 30, 2023 | 1.80M | 1.04M | 135.85% |
Jun 30, 2022 | 765.19K | 619.42K | 424.91% |
Jun 30, 2021 | 145.78K | -2.37M | -94.21% |
Jun 30, 2020 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
Jun 30, 2019 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
Jun 30, 2018 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
Jun 30, 2017 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
Jun 30, 2016 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
Sources: Historical revenue is based on company filings submitted to the U.S. Securities and Exchange Commission (SEC). The most recent revenue numbers may be taken from company press releases.
Revenue Definition
Revenue, also called sales, is the amount of money a company receives from its business activities, such as sales of products or services. Revenue does not take any expenses into account and is therefore different from profits.
Full DefinitionRelated Stocks
Company Name | Revenue |
---|---|
UnitedHealth Group | 422.82B |
Johnson & Johnson | 90.63B |
Merck & Co. | 63.62B |
AbbVie | 58.33B |
AstraZeneca | 56.50B |
Novartis AG | 55.19B |
Eli Lilly and Company | 53.26B |
Novo Nordisk | 49.11B |
IMRN News
- 14 days ago - Immuron partners with InvestorHub - GlobeNewsWire
- 7 weeks ago - Immuron - FY25 global sales exceed projection, up 49% on prior year - GlobeNewsWire
- 3 months ago - Immuron Letter to Shareholders: Projects Update - GlobeNewsWire
- 5 months ago - Immuron Travelan® highest sales in history - GlobeNewsWire
- 6 months ago - Immuron and Calmino join up to treat Irritable Bowel Syndrome (IBS) - GlobeNewsWire
- 8 months ago - Immuron Travelan® continued strong sales growth - GlobeNewsWire
- 8 months ago - Immuron Announces New Research Collaboration targeting Antimicrobial Resistance - GlobeNewsWire
- 8 months ago - Immuron Announces Travelan® Clinical Trial Update - GlobeNewsWire